Trial Profile
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined With Pembrolizumab or Cemiplimab
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Cavrotolimod (Primary) ; Cemiplimab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Leiomyosarcoma; Malignant melanoma; Merkel cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Exicure
- 30 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 10 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 10 Dec 2021 According to an Exicure media release, the company announced Discontinuation of further enrollment and the ethical wind down of the Company's ongoing Phase 1b/2 cavrotolimod (AST-008) clinical trial in patients with solid tumors